Road Ahead Still Difficult for Biosimilar Producers in US
Following news that the FDA has finalized its guidance on interchangeable biosimilars;
Rose Joachim, PhD Senior Immunology Pharma Analyst at GlobalData, a data and analytics company, offers her view on the implications for Immunology;
‘’The FDA’s new guidance is a huge step forward, however the new specifications will still make it a hard road ahead for biosimilar producers looking to make headway in the US.‘’
The FDA has specified that it does not consider post-marketing or other single-switch studies sufficient to prove the interchangeability of the product, requiring manufacturers to conduct new multi-switch studies. To date, only two large-scale studies in the immunology disease space have been conducted in this manner-one for Sandoz’s Erelzi and another for Sandoz’s Hyrimoz- both for the treatment of plaque psoriasis.
‘’Another factor that continues to complicate the utility of an interchangeability status on a biosimilar is the product’s pricing. Based on GlobalData’s analysis, in 2018 biosimilars commanded only 6% of the US infliximab market for rheumatoid arthritis four times less than the 2017 European infliximab market over a similar launch period.‘’
One of the main issues thought to be slowing the uptake of biosimilars in the US is biosimilar companies’ inability to provide competitive enough discounts to payers. Payers often have already negotiated volume-based discounts and other rebates with the company producing the reference product, making it difficult for biosimilars to compete.
‘’Even if a biosimilar is granted interchangeability status, if it ultimately cannot compete with the reference product on price, it will not be placed on a preferred tier.’’
For more information go to www.globaldata.com
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
